Evidence map›Paper›PMID 24531445›Full record

ArticleBlood cancer journal2014

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia.

A van der Veer, V H J van der Velden, M E Willemse, P G Hoogeveen, E F Petricoin, H B Beverloo, G Escherich, M A Horstmann, R Pieters, M L den Boer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A van der VeerDepartment of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
V H J van der VeldenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
M E WillemseDepartment of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
P G HoogeveenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
E F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA.
H B BeverlooDepartment of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
G EscherichCOALL Study Group, Research Institute Children's Cancer Center and Clinic of Pediatric Oncology, University Medical Center Eppendorf, Hamburg, Germany.
M A HorstmannCOALL Study Group, Research Institute Children's Cancer Center and Clinic of Pediatric Oncology, University Medical Center Eppendorf, Hamburg, Germany.
R Pieters1] Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands [2] Dutch Childhood Oncology Group, The Hague, The Netherlands.
M L den Boer1] Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands [2] Dutch Childhood Oncology Group, The Hague, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID24531445
PMCPMC3944663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.